135 related articles for article (PubMed ID: 10111726)
21. Methods of controlling cephalosporin use in Canadian hospitals.
Godin JP; Sketris IS; Merrett RA; Marrie TJ
Can J Hosp Pharm; 1988 Apr; 41(2):73-4, 83-4, 96. PubMed ID: 10287052
[TBL] [Abstract][Full Text] [Related]
22. A clinical decision process model for evaluating vancomycin use with modified HICPAC guidelines. Hospital Infection Control Practice Advisory Committee.
Salemi C; Becker L; Morrissey R; Warmington J
Clin Perform Qual Health Care; 1998; 6(1):12-6. PubMed ID: 10177043
[TBL] [Abstract][Full Text] [Related]
23. Involving physicians in efforts to control pharmaceutical expenditures.
Shulkin DJ; McGourty ME; Bourret J
Med Interface; 1995 Aug; 8(8):85-7, 90. PubMed ID: 10144777
[TBL] [Abstract][Full Text] [Related]
24. Vancomycin Use in a Brazilian University Hospital: Comparison With Hospital Infection Control Practices Advisory Committee Guidelines.
Couto HG; Leles CC; Lima HV; Assunção VF; Ribas RM; AD Filho; Gontijo PP
Braz J Infect Dis; 1999 Aug; 3(4):139-143. PubMed ID: 11096432
[TBL] [Abstract][Full Text] [Related]
25. DUE (drug usage evaluation) of ticarcillin and clavulanate potassium: determining appropriate and cost-effective therapeutic options.
Lomaestro BM; Lesar TS
Hosp Formul; 1988 Nov; 23(11):909. PubMed ID: 10312767
[TBL] [Abstract][Full Text] [Related]
26. Improving budget control: a case study.
Karali J
Hosp Cost Manag Account; 1993 May; 5(2):1-8. PubMed ID: 10125473
[No Abstract] [Full Text] [Related]
27. Metronidazole cost containment: a two-stage intervention.
Bunz D; Gupta S; Jewesson P
Hosp Formul; 1990 Nov; 25(11):1167-9, 1177. PubMed ID: 10107821
[TBL] [Abstract][Full Text] [Related]
28. Modifying empiric antibiotic prescribing: experience with one strategy in a medical residency program.
MacCosbe PE; Gartenberg G
Hosp Formul; 1985 Sep; 20(9):986-8, 993-5, 999. PubMed ID: 10274168
[TBL] [Abstract][Full Text] [Related]
29. Contribution of clinical pharmacists to cefazolin utilization.
Witte KW; Hatoum HT; Hoon TJ
Hosp Formul; 1987 Aug; 22(8):737-41. PubMed ID: 10283405
[TBL] [Abstract][Full Text] [Related]
30. Financial impact of formulary revision of second-generation cephalosporins.
Andrews JD; Hafting S
Can J Hosp Pharm; 1988 Jun; 41(3):125-7. PubMed ID: 10288499
[TBL] [Abstract][Full Text] [Related]
31. Financial impact of an aminoglycoside substitution program.
Andrews JD; Stad K
Can J Hosp Pharm; 1987 Feb; 40(1):23-6. PubMed ID: 10281256
[TBL] [Abstract][Full Text] [Related]
32. Compliance with a restricted antimicrobial agent policy in a university hospital.
Volger BW; Ross MB; Brunetti HR; Baumgartner DD; Therasse DG
Am J Hosp Pharm; 1988 Jul; 45(7):1540-4. PubMed ID: 3046348
[TBL] [Abstract][Full Text] [Related]
33. Cost benefit of pharmacy audit and nonrestrictive antibiotic policy.
Ware GJ; Ford DJ
N Z Med J; 1993 Apr; 106(954):160. PubMed ID: 8479665
[No Abstract] [Full Text] [Related]
34. Assessment of vancomycin use in chronic haemodialysis patients: room for improvement.
Zvonar R; Natarajan S; Edwards C; Roth V
Nephrol Dial Transplant; 2008 Nov; 23(11):3690-5. PubMed ID: 18565979
[TBL] [Abstract][Full Text] [Related]
35. Vancomycin overuse in Siriraj Hospital.
Rattanaumpawan P; Thamlikitkul V; Chokepaibulkit K; Lohsiriwat D; Aswapokee N
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S125-32. PubMed ID: 17718253
[TBL] [Abstract][Full Text] [Related]
36. Appropriateness of glycopeptide use in a hospital in Italy.
Bianco A; Rizza P; Scaramuzza G; Pavia M
Int J Antimicrob Agents; 2006 Feb; 27(2):113-9. PubMed ID: 16417993
[TBL] [Abstract][Full Text] [Related]
37. Economic benefit of appropriate timing of vancomycin prophylaxis in patients undergoing cardiovascular surgery.
Garey KW; Amrutkar P; Dao-Tran TK; Frost CP; Chen H; Essien EJ; Gentry LO
Pharmacotherapy; 2008 Jun; 28(6):699-706. PubMed ID: 18503397
[TBL] [Abstract][Full Text] [Related]
38. As hospital drug budgets soar, pharmacy's role is being rewritten.
Lumsdon K
Hospitals; 1992 May; 66(10):34, 36, 38-40. PubMed ID: 1577448
[No Abstract] [Full Text] [Related]
39. Effectiveness of pharmacy policies designed to limit inappropriate vancomycin use: a population-based assessment.
Thomas AR; Cieslak PR; Strausbaugh LJ; Fleming DW
Infect Control Hosp Epidemiol; 2002 Nov; 23(11):683-8. PubMed ID: 12452297
[TBL] [Abstract][Full Text] [Related]
40. Vancomycin use in a university medical center: effect of a vancomycin continuation form.
Evans ME; Millheim ET; Rapp RP
Infect Control Hosp Epidemiol; 1999 Jun; 20(6):417-20. PubMed ID: 10395144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
